Factors predicting for patient refusal of head and neck cancer therapy

Arya Amini, Vivek Verma, Richard Li, Nayana Vora, Robert Kang, Thomas J. Gernon, Sue Chang, Sana Karam, Erminia Massarelli, Ellie G. Maghami, Scott Glaser

Research output: Contribution to journalArticle

Abstract

Background: The purpose of this study was to evaluate the national rate of treatment refusal in head and neck cancer (HNC). Methods: The National Cancer Database was queried for nonmetastatic squamous cell carcinoma of the head and neck. Oncologic therapy referred to receipt of surgery, radiotherapy, or chemotherapy. Results: Compared to the 230 424 patients who received treatment, 2965 (1.3%) were reported to have refused definitive therapy. Predictors included older age, female sex, African-American/other race, nonprivate insurance, greater comorbidities, more advanced disease, and residence closer to the treating facility (P <.05). Patients with a prior history of cancer, Hispanic race, those treated at academic centers, and those from higher income counties were less likely to refuse therapy (P <.05). Patients who refused definitive therapy experienced poorer survival (median 79.1 vs 8.7 months, P <.001). Conclusions: Refusing oncologic therapy is relatively rare in HNC and appears to be multifocal in nature.

Original languageEnglish (US)
JournalHead and Neck
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Head and Neck Neoplasms
Therapeutics
Treatment Refusal
Insurance
Hispanic Americans
African Americans
Comorbidity
Neoplasms
Radiotherapy
Databases
Drug Therapy
Survival

Keywords

  • definitive treatment
  • head and neck cancer
  • radiation
  • radiotherapy
  • socioeconomic factors
  • surgery
  • treatment refusal

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Amini, A., Verma, V., Li, R., Vora, N., Kang, R., Gernon, T. J., ... Glaser, S. (Accepted/In press). Factors predicting for patient refusal of head and neck cancer therapy. Head and Neck. https://doi.org/10.1002/hed.25966

Factors predicting for patient refusal of head and neck cancer therapy. / Amini, Arya; Verma, Vivek; Li, Richard; Vora, Nayana; Kang, Robert; Gernon, Thomas J.; Chang, Sue; Karam, Sana; Massarelli, Erminia; Maghami, Ellie G.; Glaser, Scott.

In: Head and Neck, 01.01.2019.

Research output: Contribution to journalArticle

Amini, A, Verma, V, Li, R, Vora, N, Kang, R, Gernon, TJ, Chang, S, Karam, S, Massarelli, E, Maghami, EG & Glaser, S 2019, 'Factors predicting for patient refusal of head and neck cancer therapy', Head and Neck. https://doi.org/10.1002/hed.25966
Amini, Arya ; Verma, Vivek ; Li, Richard ; Vora, Nayana ; Kang, Robert ; Gernon, Thomas J. ; Chang, Sue ; Karam, Sana ; Massarelli, Erminia ; Maghami, Ellie G. ; Glaser, Scott. / Factors predicting for patient refusal of head and neck cancer therapy. In: Head and Neck. 2019.
@article{ea888c02c2c4470c933c7939e9f64fdc,
title = "Factors predicting for patient refusal of head and neck cancer therapy",
abstract = "Background: The purpose of this study was to evaluate the national rate of treatment refusal in head and neck cancer (HNC). Methods: The National Cancer Database was queried for nonmetastatic squamous cell carcinoma of the head and neck. Oncologic therapy referred to receipt of surgery, radiotherapy, or chemotherapy. Results: Compared to the 230 424 patients who received treatment, 2965 (1.3{\%}) were reported to have refused definitive therapy. Predictors included older age, female sex, African-American/other race, nonprivate insurance, greater comorbidities, more advanced disease, and residence closer to the treating facility (P <.05). Patients with a prior history of cancer, Hispanic race, those treated at academic centers, and those from higher income counties were less likely to refuse therapy (P <.05). Patients who refused definitive therapy experienced poorer survival (median 79.1 vs 8.7 months, P <.001). Conclusions: Refusing oncologic therapy is relatively rare in HNC and appears to be multifocal in nature.",
keywords = "definitive treatment, head and neck cancer, radiation, radiotherapy, socioeconomic factors, surgery, treatment refusal",
author = "Arya Amini and Vivek Verma and Richard Li and Nayana Vora and Robert Kang and Gernon, {Thomas J.} and Sue Chang and Sana Karam and Erminia Massarelli and Maghami, {Ellie G.} and Scott Glaser",
year = "2019",
month = "1",
day = "1",
doi = "10.1002/hed.25966",
language = "English (US)",
journal = "Head and Neck",
issn = "1043-3074",
publisher = "John Wiley and Sons Inc.",

}

TY - JOUR

T1 - Factors predicting for patient refusal of head and neck cancer therapy

AU - Amini, Arya

AU - Verma, Vivek

AU - Li, Richard

AU - Vora, Nayana

AU - Kang, Robert

AU - Gernon, Thomas J.

AU - Chang, Sue

AU - Karam, Sana

AU - Massarelli, Erminia

AU - Maghami, Ellie G.

AU - Glaser, Scott

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: The purpose of this study was to evaluate the national rate of treatment refusal in head and neck cancer (HNC). Methods: The National Cancer Database was queried for nonmetastatic squamous cell carcinoma of the head and neck. Oncologic therapy referred to receipt of surgery, radiotherapy, or chemotherapy. Results: Compared to the 230 424 patients who received treatment, 2965 (1.3%) were reported to have refused definitive therapy. Predictors included older age, female sex, African-American/other race, nonprivate insurance, greater comorbidities, more advanced disease, and residence closer to the treating facility (P <.05). Patients with a prior history of cancer, Hispanic race, those treated at academic centers, and those from higher income counties were less likely to refuse therapy (P <.05). Patients who refused definitive therapy experienced poorer survival (median 79.1 vs 8.7 months, P <.001). Conclusions: Refusing oncologic therapy is relatively rare in HNC and appears to be multifocal in nature.

AB - Background: The purpose of this study was to evaluate the national rate of treatment refusal in head and neck cancer (HNC). Methods: The National Cancer Database was queried for nonmetastatic squamous cell carcinoma of the head and neck. Oncologic therapy referred to receipt of surgery, radiotherapy, or chemotherapy. Results: Compared to the 230 424 patients who received treatment, 2965 (1.3%) were reported to have refused definitive therapy. Predictors included older age, female sex, African-American/other race, nonprivate insurance, greater comorbidities, more advanced disease, and residence closer to the treating facility (P <.05). Patients with a prior history of cancer, Hispanic race, those treated at academic centers, and those from higher income counties were less likely to refuse therapy (P <.05). Patients who refused definitive therapy experienced poorer survival (median 79.1 vs 8.7 months, P <.001). Conclusions: Refusing oncologic therapy is relatively rare in HNC and appears to be multifocal in nature.

KW - definitive treatment

KW - head and neck cancer

KW - radiation

KW - radiotherapy

KW - socioeconomic factors

KW - surgery

KW - treatment refusal

UR - http://www.scopus.com/inward/record.url?scp=85073930276&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073930276&partnerID=8YFLogxK

U2 - 10.1002/hed.25966

DO - 10.1002/hed.25966

M3 - Article

C2 - 31584746

AN - SCOPUS:85073930276

JO - Head and Neck

JF - Head and Neck

SN - 1043-3074

ER -